The ASX 200 has bounced back following a $25 billion wipeout on Wednesday triggered by Donald Trump escalating his trade war ...

AI could inject an additional $461 billion into the healthcare sector by 2035, according to Accenture, as it races past the $2.26 trillion mark. This shift isn't just about diagnostics or ...

After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price ...

Key Points Adjusted EPS reached $2.77 in Q2, topping estimates by $0.09, but fell year over year. Revenue rose 5.8% year over year to $23.7 billion, exceeding estimates by $889 million. Full-year 2025 ...

"When I see a bubble forming, I rush in to buy, adding fuel to the fire."— George Soros Bubbles are not just market anomalies ...

Windtree Therapeutics signs $60M deal for BNB treasury strategy, becoming the first Nasdaq firm to offer direct exposure to ...

J&J (NYSE:JNJ) stock surges rallying peers despite Trump's latest tariff threats on pharma as the company posts a quarterly ...

This cancer treatment stock is nearing a buy point of a base. Shares have already gained 50% so far this year.

SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the ...

Stocks were taken on a wild ride Wednesday as a White House official indicated to CNBC that Trump was moving closer to firing ...

Is it safe to get into the water? If "Jaws" taught us anything, it was to be cautious of your surroundings before going for a ...

Lilly, Johnson & Johnson, AbbVie, Pfizer and more pharma stocks shrug even amid Trump's fresh pharma tariff threats.